Chemomab Therapeutics Ltd. (CMMB) News
Follow Chemomab Therapeutics Ltd. (CMMB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
SEC Declares Registration Statement Effective for Chemomab-Scipher Deal
MNA | Nov 03, 2026, 01:17 PM UTC
L
Chemomab Therapeutics reports Q2 2026 results, corporate update
Chemomab Therapeutics (CMMB) announces its second quarter 2026 financial results and provides a corporate update, according to the company release.
EARNINGS | Aug 19, 2026, 12:26 PM UTC
H
Top Midday Decliners
() -- Chemomab Therapeutics (CMMB) and Scipher Medicine have entered into an all-stock merger agreement, the companies said Wednesday. Shares of Chemomab dropped 14% as intraday trading volume jumped to over 1.79 million
MNA | Jul 08, 2026, 06:07 PM UTC
H
Chemomab Therapeutics, Scipher Medicine to Merge in All-Stock Deal
() -- Chemomab Therapeutics (CMMB) and Scipher Medicine have entered into an all-stock merger agreement, the companies said Wednesday. Under the terms of the merger, Chemomab equity holders are expected to own around 32%
MNA | Jul 08, 2026, 12:17 PM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC